New PD-L1 inhibitors

This topic has 3 replies, 1 voice, and was last updated 9 years, 7 months ago by Bubbles.

Post

- May 19, 2016 at 5:32 pm
- Quote
JohnA
Participant
Hey folks,

These are being tested in other cancers, but I wonder if they will come to have relevance for the melanoma community?

I thought some of you might be interested-

John

In the 61-patient study, about 30 percent of those with Merkel skin cell carcinoma treated with Merck's avelumab saw their tumors shrink or disappear.

Avelumab, which German Merck is developing with Pfizer Inc , belongs to a class of drugs called PD-L1 inhibitors that block a mechanism tumors use to hide from the immune system, allowing it to recognize and attack the cancer. They are closely related to the PD-1 drugs already on the market from Bristol-Myers Squibb (Opdivo) and Merck & Co (Keytruda) seen as major advances against melanoma, lung cancer and other malignancies.

Roche's Tecentriq earlier on Wednesday became the first approved PD-L1 drug, gaining U.S. approval to treat advanced bladder cancer.

Viewing 2 reply threads

Replies

- - May 19, 2016 at 11:47 pm
  - Quote
  Bubbles
  Participant
  Yes, it's pretty cool stuff! I posted this today….which also includes data from Tecentriq trial in melanoma that Weber mentioned in his 2016 webinar re immunotherapy: http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2016/05/atezolizumab-renamed-tecentriq-fda.html
  
  Thanks for sharing! Celeste
- - May 19, 2016 at 11:47 pm
  - Quote
  Bubbles
  Participant
  Yes, it's pretty cool stuff! I posted this today….which also includes data from Tecentriq trial in melanoma that Weber mentioned in his 2016 webinar re immunotherapy: http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2016/05/atezolizumab-renamed-tecentriq-fda.html
  
  Thanks for sharing! Celeste
- - May 19, 2016 at 11:47 pm
  - Quote
  Bubbles
  Participant
  Yes, it's pretty cool stuff! I posted this today….which also includes data from Tecentriq trial in melanoma that Weber mentioned in his 2016 webinar re immunotherapy: http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2016/05/atezolizumab-renamed-tecentriq-fda.html
  
  Thanks for sharing! Celeste

Viewing 2 reply threads

Tagged: cutaneous melanoma

You must be logged in to reply to this topic.

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.